What is CAR-T Therapy?
CAR-T therapy uses the power of your own immune system to fight blood cancers like lymphoma, leukemia, and myeloma. The process involves collecting a patient's own T-cells (a type of white blood cell), re-engineering them in a specialized manufacturing facility so they can better recognize and attack cancer cells.
These "supercharged" cells are then expanded into millions and re-infused into the patient. Once inside the body, CAR-T cells continue to hunt down cancer cells for months or even years.
1. COLLECTION
Patient's T-cells are collected through a process called apheresis
2. ENGINEERING
T-cells are re-engineered in the lab to better recognize cancer cells, then expanded into millions
3. RE-INFUSION
Enhanced CAR-T cells are returned to fight cancer for months or years
Affordable CAR-T and Hospital Costs in China
CAR-T Therapy is exceptionally affordable in China, thanks to localized manufacturing of US and European pharma companies, and centralized national procurement program that negotiates down prices for patients. Hospital costs are subsidized and regulated to maximize affordability, and available for foreigners too.
United States
$400,000 - $500,000
Singapore
$300,000 - $400,000
Hong Kong
$190,000 - $290,000
China
$90,000 - $180,000
Capabilities in China vs Other Countries
China's leadership in CAR-T clinical research and development
Clinical Excellence & Expertise
China is now the leading country for CAR‑T clinical research, running more clinical trials than any other nations in their hospitals, thus giving their doctors deep expertise in CAR-T and nurses extensive hands‑on experience with these therapies. This depth of practice supports better treatment decisions and safer management of side effects such as CRS and ICANS, thus better clinical outcomes.
More clinical trials than any nation
Extensive nursing experience
Deep physician expertise
Better clinical outcomes
Global CAR-T Manufacturing Hub
Global companies are also choosing China as a key manufacturing and development base for CAR‑T, such as production of cilta‑cel (Carvykti) for use in the United States and Europe, alongside a fast‑growing group of local innovators working on next‑generation CAR‑T products. As a result, some of the most advanced CAR‑T options are first, or only, available to patients treated in China.
Global Production
For US & Europe
Local Innovation
Next-gen products
First Access
Advanced options
CART Products Overview
Advanced CAR-T therapies with superior efficacy and safety profiles
Axi-cel
Proven Track Record Since 2017
✓ Regulatory Approval
US FDA approved for LBCL and FL since 2017
🏭 Manufacturing
Kite Pharma (Gilead) & Fosun Pharma Joint Venture
Shanghai Manufacturing
📈 Efficacy
80%+ ORR
🛡️ Safety Profile
90%+ of patients developed only mild complications
⭐ Key Highlights
•First to market
•Extensive clinical data
•Proven safety profile
Relma-cel (Liso-cel)
Enhanced Long-term Efficacy
✓ Regulatory Approval
US FDA approved for LBCL, FL, CLL/SLL and MCL (2021-24)
🏭 Manufacturing
Juno Therapeutics (Bristol Myers Squibb) & WuXi AppTec
Shanghai Manufacturing (JW Therapeutics - HK Listed)
📈 Efficacy
~80% ORR
🛡️ Safety Profile
95% of patients developed only mild complications
⭐ Key Highlights
•Superior long-term outcomes
•Broader indications
•Public company backing
Zevor-cel
BCMA-directed Fully Human scFv
✓ Regulatory Approval
China NMPA approved for RRMM (2024), US FDA Phase II ongoing
🏭 Manufacturing
BCMA-directed fully human scFv technology
China-developed innovation
📈 Efficacy
>90% ORR, depth of response increasing with time
🛡️ Safety Profile
90% of patients experienced only mild complications
⭐ Key Highlights
•Fully human lentivirus
•Exceptionally high efficacy
•Increasing efficacy over time
Eque-cel
BCMA-directed
✓ Regulatory Approval
NMPA approved for RRMM (2023), US FDA IND ongoing
🏭 Manufacturing
IASO Biotherapeutics
China-developed Innovation
📈 Efficacy
95%+ ORR
🛡️ Safety Profile
90%+ of patients developed only mild complications
⭐ Key Highlights
•Fully human lentivirus
•Exceptionally high efficacy
•Increasing efficacy over time
Puzol-cel
Affordable option for children
✓ Regulatory Approval
NMPA approved for Pediatrics B-ALL (2025)
🏭 Manufacturing
Precision Biotech
China-developed Innovation
📈 Efficacy
>90% CR/CRi, >70% response maintained at 3 months
🛡️ Safety Profile
~70% of patients developed only mild complications
⭐ Key Highlights
•Most affordable pediatrics CAR-T
•High efficacy and long-lasting response
Pilot Use CAR-T
Latest technology in CAR-T
✓ Regulatory Approval
Post Phase II clinical trial with solid data. Approved for pilot use in selected leading hospitals only.
🏭 Manufacturing
Various biotech companies
China-developed innovation
📈 Efficacy
Generally similar ORR around 80%. New tech e.g. new antigen targets, and dual-target CAR-T promises more sustained long-term survival.
🛡️ Safety Profile
Generally safer due to usage of fully humanized viral vectors
⭐ Key Highlights
•Fully human design
•Latest technology
•Much more affordable than commercialized products
Hospital Facilities
State-of-the-art facilities equipped with cutting-edge technology for CAR-T cell therapy manufacturing and patient care.
CAR-T Patient Treatment Journey: 7-9 weeks
Your comprehensive guide through each stage of CAR-T cell therapy, from initial evaluation to post-treatment monitoring
Medical evaluation
before you travel
We review your medical history, scans, lab results, treatment records, and current medications, then arrange an online consultation to confirm if CAR‑T is appropriate for you and to answer your questions.
Apheresis
cell collection, 3-5 days on site
You are admitted for basic checks (for example, infection screening and liver and kidney function tests), followed by the apheresis procedure itself, where your T cells are collected over 4–6 hours. Deposit is due at the hospital upon arrival (no payments needed before this).
CAR‑T infusion
about 1 week
You receive pre‑treatment medicines and a short course of chemotherapy for lymphodepletion, then the CAR‑T cells are infused back into your bloodstream in a procedure that usually takes around 30 minutes.
Leukapheresis preparation
1 week before collection
Stop disease‑directed treatments and non‑essential medicines 1 week before leukapheresis, and you will be asked to share your most recent test results.
T‑cell engineering and expansion
3 weeks
Your collected T cells are genetically modified and expanded in the lab; during this time you may either return home or stay in Hong Kong / China, and your medical team may recommend bridging therapies to minimize tumor load.
Monitoring and managing side effects
about 2–4 weeks
After infusion you are closely monitored for complications such as cytokine release syndrome (CRS) and ICANS, and the length of your hospital stay will depend on the severity of any side effects.
CAR-T Patient Journey
1-2 overseas trips, 4-6 weeks in total
1
Assessment & Apheresis
Pre-assessment and apheresis to collect T-cells
2
Engineering & Expansion
Return home while T-cells are engineered and expanded in the manufacturing facility
3
Infusion & Monitoring
CAR-T cell infusion with inpatient monitoring and complication management
Total Treatment Period
7-9 weeks
Exact duration depending on the degree of complication management required